The proposed tax-free spinoff, targeted for the first half of 2028, would leave Aetna and pharmacy benefit manager Caremark together in CVS Health while creating a separately traded CVS Pharmacy. Existing shareholders would own stock in both companies, subject to final approvals and terms that have not yet been announced.
What CVS plans to separate
| Company after separation | Principal operations | Planned chief executive |
|---|---|---|
| CVS Health | Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health | David Joyner |
| CVS Pharmacy | About 9,000 retail pharmacies, mail pharmacy, MinuteClinic (including virtual care), and Health100 technology services | Prem Shah |
The allocation of mail pharmacy to CVS Pharmacy and specialty pharmacy to the remaining CVS Health is an important boundary. CVS’s drug dispensing, benefits management and insurance operations currently transact extensively with one another, so the companies will need commercial relationships after the separation. A standalone drugstore company may be easier for investors to value, but its economics will depend in part on the pricing and duration of those arrangements.
The drugstore segment is profitable, but it is not yet a standalone company
CVS’s third-quarter results put Pharmacy & Consumer Wellness revenue at $35.50 billion and adjusted operating income at $1.64 billion, a 4.6% margin. Revenue declined 2.0% from a year earlier while adjusted operating income rose 10.6%. Over the first nine months of 2026, the segment reported $101.30 billion of revenue and $4.31 billion of adjusted operating income, a 4.3% margin.
Those results are a starting point for valuing CVS Pharmacy, not a pro forma income statement. The November 4 Form 10-Q shows that $32.20 billion of the segment’s nine-month revenue came from transactions with other CVS units. The spinoff’s asset boundaries, new service agreements, standalone overhead and debt allocation could materially change the figures that ultiMove to Trashmately belong to CVS Pharmacy shareholders.
CVS also reported $2.09 in third-quarter adjusted earnings per share, compared with $1.60 a year earlier, and raised its 2026 adjusted EPS outlook to at least $8.20. Those consolidated earnings figures do not establish the profitability or value of either future company.
The remaining CVS Health still faces 340B and Medicare Advantage pressures
The morning selloff cannot be attributed to the spinoff alone. Barron’s reported investor concern over uncertainty in the federal 340B drug-discount program, which has faced manufacturer restrictions and affects CVS’s Health Services operations. CVS’s new 10-Q says the changing 340B environment may continue to affect that segment; the company has not provided a firm estimate of the potential 2027 earnings impact.
Aetna presents a separate issue for the company retaining the CVS Health name. The 10-Q says more than 69% of its Medicare Advantage members were in plans receiving at least four stars in the 2027 ratings, versus more than 81% under the 2026 ratings, using membership snapshots from September of each respective year. The 2027 ratings determine eligibility for Medicare Advantage quality-bonus payments in 2028, when the separation is expected to occur. The disclosure indicates a potential pressure on future bonus revenue, but does not quantify the earnings effect.
Keeping Aetna and Caremark together also means CVS is retaining a substantial part of its integrated insurance-and-PBM model. The breakup separates retail pharmacy ownership from that structure, rather than fully disentangling the businesses that negotiate drug benefits and reimbursements.
The missing terms will determine what shareholders receive
CVS expects both companies to maintain investment-grade credit ratings and pay dividends, but has not disclosed a share-distribution ratio, debt allocation, future dividend amounts or a new ticker. Nor has it published carve-out financial statements for the proposed businesses. For comparison, Abbott’s recently announced Nutrition spinoff already included an intended debt-funded transfer to the parent; CVS has provided no comparable capital-allocation detail.
The transaction remains subject to CVS board approval, an effective Form 10 registration statement and confirmation of its intended tax-free treatment. Investors will need the standalone financials and the contracts between CVS Pharmacy and CVS Health before they can make a meaningful sum-of-the-parts comparison. The first-half-2028 date is a target, not an established distribution date.